


Cardiovox

Preventing atherosclerosis



Suggested treatment and development stage:

Immunization with apo B-100 derived peptides has been shown to inhibit atherosclerosis development in mice. Pre-clinical trials have been completed and an IND application has been filed with FDA.

Existing treatment:

Statins, niacin, intestinal cholesterol absorption-inhibiting supplements, dietary supplements, surgical intervention

Unmet need:

Treatment of advanced plaques in clinical care emphasizes on reducing plaque inflammation rather than inducing plaque regression.

Target group:

Male, female past menopause, high blood pressure, smokers, obese, diabetics etc – everyone in the riskzone of developing atherosclerosis.

Market:

“Cardiovascular Pharmaceutical Market Trends 2007 to 2010 - Key Market Forecasts and Growth Opportunities” reports that the global cardiovascular market is forecast to expand to US \$116 billion in 2010

Intellectual property:

Patents issued in the US, Europe (22 countries), Australia, and Russia

Strategy:

Optional investment need of US \$1 million to defend ownership position

Contact:

Dr. Bert Junno, Lund University Technology Group, +46-707-772209, bert.junno@forskarpatent.com

Dr. Mikael Lindstam, Lund University Technology Group, +46-766-333699, mikael.lindstam@forskarpatent.com